Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small, non-discretionary share sale tied to taxes. On April 18, 2026, 33 Ordinary Shares were sold in the open market at an average price of $5.0816 per share to satisfy tax obligations from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 148,197 Ordinary Shares.
SOPH insider reported proposed and completed stock sales under a Form 144 and 10b5-1 plan. The filing lists Restricted Stock Units granted with entries of 608 shares (04/18/2026) and 10,000 shares (01/03/2025). Multiple 10b5-1 sales are shown, including 5,000-share trades on 03/12/2026 and 02/12/2026, and smaller sales across February–April 2026.
Jurgi Camblong reported multiple planned sales of Common Stock under a Rule 10b5-1 plan. The filing lists discrete 10b5-1 sale transactions across 2026 (example: 37,299 shares on 01/22/2026 for $209,917.83) and shows Restricted Stock Units (4,486) and Founders Shares (8,500) referenced.
SOPH (Form 144) reports a notice to sell 380 restricted stock units of Common Stock dated 04/18/2026. The filing also lists multiple Rule 10b5-1 open-market sales by Manuela Valente totaling several transactions in Feb–Apr 2026, with individual sell amounts and gross proceeds reported.
SOPH filing (Form 144) reports proposed sales of Common Stock, showing multiple 10b5-1 sales by Zhenyu Xu and scheduled dispositions of restricted and founder shares. Examples include 4,414 shares sold on 04/13/2026 for $21,026.97 and a 608-share RSU entry dated 04/18/2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice related to SOPH common stock, reporting 760 shares of restricted stock units to be sold on 04/18/2026. The filing also lists multiple 10b5-1 sales by Ross J. Muken during Feb–Apr 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting a proposed sale of 684 Restricted Stock Units (Common) dated 04/18/2026. The filing also lists recent 10b5-1 sales by Daan Guido Maria van Well, including 2,400 shares on 04/10/2026 for $11,201.28 and 2,861 shares on 04/08/2026 for $13,862.12.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 600 ordinary shares on April 14, 2026 at a weighted average price of $4.9663 per share. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, and Xu continued to hold 631,496 ordinary shares directly after the transaction.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine share sales tied to tax obligations. On April 14 and 15, 2026, he sold a total of 60,602 ordinary shares in open-market transactions at weighted average prices of $4.9580 and $5.0021 per share. The filing states these sales were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After these transactions, he continues to hold 3,646,967 ordinary shares directly.
Chief Medical Officer Philippe Menu of SOPHiA GENETICS SA sold 1,600 ordinary shares in an open-market transaction on April 14, 2026. The shares were sold at a weighted average price of $4.9581 per share under a pre-established Rule 10b5-1(c) trading plan.
Following this sale, Menu directly holds 266,996 ordinary shares. The transaction was executed through multiple trades at prices ranging from $4.78 to $5.16 per share.